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The efficacy of a drug in a specific application requires the maintenance of appropriate drug blood level 
concentration during a prolonged period of time. Controlled release delivery is available for many routes 
of administration and offers many advantages (as microparticles and nanoparticles) over immediate 
release delivery. These advantages include reduced dosing frequency, better therapeutic control, fewer 
side effects, and, consequently, these dosage forms are well accepted by patients. Advances in polymer 
material science, particle engineering design, manufacture, and nanotechnology have led the way to 
the introduction of several marketed controlled release products and several more are in pre-clinical 
and clinical development. The objective of this work is to prepare and evaluate diltiazem HCl loaded 
albumin microparticles using a factorial design. Albumin (natural polymer) microparticles were prepared 
by emulsion heat-stabilization method. Selected formulations were characterized for their entrapment 
efficiency, particle size, surface morphology, and release behavior. Analysis of variance for entrapment 
efficiency indicates that entrapment efficiency is best fitted to a response surface linear model. Surface 
morphology was studied by scanning electron microscopy. Scanning electron microscopy of the 
microparticles revealed a spherical, nonporous and uniform appearance, with a smooth surface. The 
geometric mean diameter of the microparticles was found to be 2-9 μm, which more than 75% were 
below 3.5 μm and drug incorporation efficiency of 59.74 to 72.48% (w/w). In vitro release profile for 
formulations containing diltiazem HCl loaded BSA microparticles with heat stabilization technique shows 
slow controlled the release of the drug up to 24 hours. The release pattern was biphasic, characterized 
by an initial burst effect followed by a slow release. All selected microparticles exhibited a prolonged 
release for almost 24 hours. On comparing regression-coefficient (r2) values for Hixson Crowel, 
Higuchi and Peppas kinetic models, different batches of microparticles showed Fickian, non-Fickian, 
and diffusion kinetics. The release mechanism was regulated by D:P ratio. From the statistical analysis 
it was observed that as the drug:polymer (D:P) ratio increased, there was a significant increase in the 
encapsulation efficiency. Based on the particle size, entrapment efficiency and physical appearance, 
DTM-3 formulations were selected for in vivo release study and stability study. The in vivo result of 
drug loaded microparticles showed preferential drug targeting to liver followed by lungs, kidneys and 
spleen. Stability studies showed that maximum drug content and closest in vitro release to initial data 
were found in the formulation stored at 4 ºC. In present study, diltiazem HCl loaded BSA microparticles 
were prepared and targeted to various organs to satisfactory level and were found to be stable at 4 ºC.
Uniterms: Diltiazem HCl loaded microparticles/preparation. Diltiazem HCl loaded microparticles/ 
release profile/evaluation. Albumin/microparticles. Microparticles batches/diffusion kinetics.
A eficácia terapêutica de um fármaco depende da manutenção de seu nível plasmático adequado em 
determinado intervalo de tempo. Nesse sentido, a liberação modificada de fármacos está disponível 
em muitas vias de administração e oferece muitas vantagens (como micropartículas e nanopartículas) 
quando comparada às formulações de liberação imediata. Essas vantagens incluem reduzida frequência da 
dosagem, melhor controle terapêutico e menos efeitos colaterais. Assim sendo, esses produtos apresentam 
maior aceitação pelos pacientes. Os avanços na ciência dos materiais, na engenharia das partículas, em 
manufatura e em nanotecnologia permitiram a introdução no mercado de vários produtos de liberação 
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modificada e vários outros se encontram em desenvolvimento pré-clínico e clínico. O objetivo do 
presente trabalho foi preparar e avaliar o fármaco cloridrato de diltiazem associado a micropartículas de 
albumina utilizando planejamento fatorial. As micropartículas de albumina, um polímero natural, foram 
preparadas por método de emulsão empregando estabilização por calor. As formulações selecionadas 
foram caracterizadas no que se refere à sua eficiência de encapsulamento, tamanho médio de partículas, 
morfologia de superfície e perfil de liberação do fármaco. A análise de variância relativa à eficiência de 
encapsulamento indicou superfície de resposta linear. Com referência à morfologia superficial, essa foi 
avaliada empregando microscopia eletrônica de varredura. Essa análise revelou micropartículas esféricas, 
não porosas e de aparência uniforme, com superfície lisa. O diâmetro médio das micropartículas foi entre 
2 e 9 μm, sendo que mais de 75% das micropartículas se apresentaram abaixo de 3,5 μm. Além disso, 
a eficiência de encapsulamento foi entre 59,74 e 72,48%. Quanto ao ensaio para avaliação do perfil de 
liberação in vitro do fármaco associado às micropartículas, as formulações apresentaram liberação lenta 
até 24 horas. O comportamento foi caracterizado por liberação inicial (efeito burst) seguida por liberação 
lenta. Todas as fórmulas selecionadas apresentaram liberação prolongada por aproximadamente 24 horas. 
Na comparação entre os valores de coeficientes de regressão (R2), os modelos propostos por Hixson 
Crowel, Higuchi e Peppas, para diferentes formulações de micropartículas, demonstraram cinética de 
liberação de acordo com modelo Fickiano e não-Fickiano. O mecanismo de liberação do fármaco foi 
regulado pela razão entre o fármaco e o polímero. A análise estatística revelou significativo aumento da 
eficiência de encapsulamento quando essa razão aumentou. As avaliações relativas à análise dimensional 
das micropartículas, à eficiência de encapsulamento do fármaco e à morfologia permitiram a seleção 
da formulação DTM-3 para os ensaios de liberação in vivo e para o estudo da estabilidade. O ensaio de 
liberação in vivo do fármaco associado às micropartículas demonstrou sítio-alvo preferencial no fígado, 
seguido pelos pulmões rins e baço. No presente estudo, as micropartículas de albumina contendo cloridrato 
de diltiazem foram adequadamente preparadas e orientadas satisfatoriamente para vários órgãos. Além 
disso, a formulação selecionada apresentou estabilidade físico-química a 4 oC.
Unitermos: Cloridrato de diltiazem/associado a micropartículas/preparação. Cloridrato de diltiazem/
associado a micropartículas/avaliação do perfil de liberação. Albumina/micropartículas. Formulações 
de micropartículas/cinética de liberação.
INTRODUCTION
The efficacy of a drug in a specific application re-
quires the maintenance of appropriate drug blood level 
concentration during a prolonged period of time. However, 
the conventional administration of drugs, gives a poor 
control of the concentration of these substances in plasma 
because of variations in the concentration of the bioactive 
product, once a specific dose has been administered. The 
conventional dosage systems can rise to alternative periods 
of inefficacy or toxicity. These difficulties have been called 
for the development of new administration techniques for 
bioactive compounds, directed towards attaining the steady 
state plasma concentration. In the recent years, considerable 
attention has been focused on the development of Novel 
Drug Delivery Systems (NDDS). The reason for this para-
digm shift is due to the low development cost and time re-
quired for developing a NDDS for the existing drugs rather 
developing a new drug molecule. In the form of NDDS, 
existing drug molecule can get a new life, thereby increasing 
the market value and product patent life. Controlled release, 
prolonged action, sustained release, extended release, depot 
dosage forms are terms used to identify these drug delivery 
systems that are designed to achieve prolonged therapeutic 
effected by continuously releasing medication over an 
extended period of time after administration of single dose 
(Chinna et al., 2010). The therapeutic benefits of new sys-
tems include increased efficacy of the site-specific delivery, 
decreased toxicity/side effects, increased convenience, 
shorter hospitalizations, variable treatments for previously 
incurable diseases, potential for prophylactic applications 
and lower healthcare costs–both long term and better patient 
compliance (Lee et al., 2000; Lalla, 1991). In a majority 
of studies the homo and copolymer have been used for 
drug delivery application because they can be fabricated 
into a variety of morphologies, including films, rods, and 
microparticles by compression molding, solvent casting, 
solvent evaporation technique and phase separation tech-
nique (Chinna et al., 2010).
Biodegradable polymers have been of long interest 
in controlled release technology because of the ability of 
these polymers to be reabsorbed by the body. This allevi-
ates the need for removal, often surgically, of a drug release 
device. Knowledge and skill in the field of biodegradable 
polymer technology is progressing rapidly enough that 
researchers have at their disposal a substantial number of 
degradable polymers with a range of degradation rates. Not 
only the researchers may use a single polymer, copolymer, 
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or blend, but also they may use a combination of polymers. 
These polymers, which have been prepared as films, mic-
roparticles, rods, and other forms, display a bulk erosion 
hydrolysis (Pappas et al., 1995; Mansour et al., 2010).
While biodegradable microparticles have proven 
to be useful in a wide range of controlled drug delivery 
applications, several research groups have investigated 
opportunities for utilizing biodegradable microparticles 
in composite or hybrid systems with other biodegradable 
or non-degradable systems. The release rates and profiles 
of both hydrophilic drugs and hydrophobic drugs have 
shown to be significantly changed when the biodegradable 
microparticles containing these drugs are incorporated 
into silicone (nondegradable) or gelatin (degradable) 
films. The drug released from the microparticles within 
the silicone films does not exhibit the initial high burst 
of release in vitro from free microparticles (Pappas et al., 
1995). Naturally derived polymers are abundant and usu-
ally biodegradable. Their principal disadvantages lie in the 
development of reproducible production methods, because 
their structural complexity often renders modification and 
purification difficult. Additionally, significant batch-to-
batch variations occur because of their ‘biopreparation’ 
in living organisms (Nela et al., 1999).
Microparticulates in the size range of about 1-100 
μm, consisting of biodegradable or bioerodible solids with 
embodied therapeutic agents, represent a prominent class of 
delivery systems. Their administration is most commonly 
by local injection of suitable dispersions but applications 
to the respiratory tract or peroral delivery are equally inter-
esting. In particular, there is much interest currently in the 
use of biodegradable polymers for the preparation of mic-
roparticles containing a wide range of therapeutic agents, 
which can, of course, be used for parenteral administration. 
Solid biodegradable microparticles incorporating a drug 
dispersed throughout the particle matrix have the potential 
for the controlled release of the drug from this system after 
i.m. injection. Microparticles designed for parenteral drug 
delivery can be composed of a variety of materials with 
different physical characteristics such as biocompatible, 
biodegradable, injectable, sterile, compatible with diluents, 
and pharmaceutically stable. Depending on the used mic-
roparticulate material, its size distribution and degradation 
or erosion kinetics, various delivery profiles are feasible 
(Merkle et al., 2002; Nanjwade et al., 2011).
The therapeutic and economic success of micropar-
ticulates as a delivery platform is related closely to the 
advent of therapeutics from biotechnological sources. 
For future development, the following prospects for this 
class of drug delivery systems are envisaged (Merkle et 
al., 2002):
•	 Innovations for novel biodegradable and biocom-
patible materials and additives for better control of 
delivery kinetics;
•	 Improvements of manufacturing techniques in terms 
of narrow particle size distribution, high loading 
efficiency, aseptic manufacturing technologies and 
drug stability;
•	 Development of microparticulates as tools in tissue 
engineering, for example, to establish localized 
gradients of mitogenic or morphogenic agents and 
support organized tissular development;
•	 Exploration of novel therapeutic opportunities 
through the use of microparticulates for systemic 
and localized delivery;
•	 Innovations regarding novel materials and surface 
modifications to improve on biocompatibility and 
targeting features of microparticulates;
•	 Design of microparticulates for optimized delivery 
of antigens to professional antigen-presenting cells.
Several techniques can be used to prepare polymeric 
microparticles providing controlled drug delivery. Most 
commonly, organic solvent evaporation and/or extraction 
methods are applied. Depending on the solubility of the drug 
simple or multiple emulsion technique, oil-in-water (o/w) 
and water-in-oil-in-water (w/o/w) methods are used. In the 
first case, a lipophilic drug is dissolved together with the 
polymer in an organic phase, which is dispersed into outer 
aqueous phase. Upon contact, the organic solvent diffuses 
into the external water phase and evaporates at its surface. 
Consequently, the polymer precipitates and entraps the drug. 
If a drug hydrophilic is to be incorporated, it can generally 
not be dissolved within organic phase and drug loss into the 
external aqueous phase tends to be remarkable, resulting in 
low encapsulation efficiencies. To overcome this restric-
tion w/o/w techniques can be applied, avoiding the direct 
contact of the drug containing phase with the outer water 
phase. An aqueous solution of the drug is emulsified into an 
organic phase containing the dissolved polymer. This w/o 
emulsion is dispersed into an outer aqueous phase. Upon 
solvent diffusion/evaporation, the polymer precipitates and 
incorporates the drug (Perez et al., 2003).
Albumin microparticles are biodegradable particles 
that can be produced in a size range of 1 to 200 μm in 
diameter, by either physical or chemical solidification of 
an albumin emulsion in an organic phase. Bovine serum 
albumin (BSA) is widely used for microparticles prepara-
tion because it is non-antigenic, biodegradable, free from 
toxicity, able to control the physicochemical characteris-
tics of the microparticles produced, and readily available 
(Mathew et al., 2007).
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Microparticles of bovine serum albumin (BSA) may 
be prepared using an emulsion of aqueous BSA in oil. Suf-
ficient elevation of the temperature of the emulsion will 
set the BSA microparticles or polymerization of polymer 
by using cross-linking agents. Any drug may be included, 
either in solution along with the BSA or in suspension, for 
water-insoluble drugs. The microparticles are cooled and 
then washed with ether (or another appropriate solvent) 
and collected usually by filtration or centrifugation (Birn-
baum et al., 2003).
Diltiazem hydrochloride, a calcium channel blocker, 
is widely used for the treatment of angina pectoris, hyperten-
sion and arrhythmias. It is administered orally (tablets, cap-
sules, sustained release tablets/capsules) and parenterally 
(intravenous). Diltiazem hydrochloride is a water-soluble 
cardiovascular drug. The usual dose of diltiazem is 90-120 
mg. The conventional tablet and capsule is administered 3 
or 4 times a day due to its short biological half-life of about 
6 h. The problems of frequent administration and variable 
low bioavailability (30-45%) after oral administration of 
conventional tablet or capsules have been attenuated by 
designing diltiazem in the form of sustained release tablet or 
capsules. The sustained release forms are administered two 
times a day due to its limited residence time in the gastroin-
testinal tract. These limitations of diltiazem hydrochloride in 
conventional dosage form, sustained release tablet or cap-
sules can be overcome by administrating diltiazem hydro-
chloride by other route of administration (Das et al., 2008).
The purpose of the present study is to prepare diltia-
zem hydrochloride microparticles using bovine serum al-
bumin (biodegradable natural polymer) by emulsification-
heat stabilization technique and to investigate the effect of 
microparticle structure and drug release from them.
MATERIAL AND METHODS
Material
Diltiazem hydrochloride BP was supplied by Neu-
land Laborotaries Ltd., Hyderabad (A.P., India) and Bo-
vine serum albumin (BSA fraction V) was purchased from 
LOBA Chemie Pvt. Ltd. (Mumbai, India). Cottonseed oil 
was purchased from Acros organics (New Jersey, USA).
Formulation of microparticles of diltiazem HCl 
(Dandagi et al., 2006; Kristina et al., 2001; Tuncay et 
al., 2000; Arshady, 1990)
Table I represents the design of various formulations 
developed. BSA microparticles containing diltiazem HCl 
were prepared by emulsification-heat stabilization technique 
(Figure 1: show the systemic diagram of emulsification-heat 
stabilization technique). One hundred fifty milligrams BSA 
was dissolved in 3 mL deionised water containing 0.1% 
(v/v) Tween 80, to which 100 mg diltiazem hydrochloride 
was added and used as the aqueous phase. The oil phase 
comprised of 3 mL cottonseed oil and 1 mL petroleum ether 
with 1% (v/v) Span 80 (as emulsifier), which mixed together 
and allowed to stir for 15 min at 1000 rpm on a magnetic 
stirrer. The aqueous phase was added drop wise to the oil 
phase and stirred for 45 min to form the primary emulsion. 
This primary emulsion was then added to 100 mL of cot-
tonseed oil preheated to 115–120 ºC using 21 No. needle 
and stirred at 1200 rpm for 1 hours to allow the formation 
and solidification of microparticles. The suspension was 
then allowed to cool to room temperature with continuous 
stirring using a magnetic stirrer for 3 hours. On cooling, 150 
mL of anhydrous ether was added. The suspension contain-
ing the microparticles was centrifuged at 3500 rpm for 15 
min and the settled microparticles were washed three times 
with ether to remove traces of oil on microparticles surfaces. 
The obtained microparticles were then vacuum dried in a 
desiccator overnight and stored at 4 ºC in dark. Four batches 
of microparticles were prepared by the above-mentioned 
methods and labeled as DTM-1, DTM-2, DTM-3, and 
DTM-4. (Table I).
Characterization of microparticles
Calculation of percentage yield of microparticles 
(Salem et al., 2011; Yeo et al., 2004)
The yield of each formula was calculated by divid-
TABLE I - Formulation design, drug entrapment efficiency & average size distribution of microparticles of different formulations
Batch Formula (Drug:Polymer) % yield Drug Entrapment 
Efficiency in % (w/w)
Average particle 
size in µm
DTM-1 1:1.50 65.46 59.74 2.17
DTM-2 1:1.75 66.78 64.26 2.34
DTM-3 1:2.00 70.84 69.51 2.48
DTM-4 1:2.50 72.82 72.48 8.25
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FIGURE 1 - General diagram of Emulsification-Heat Stabilization technique for Microparticles formulation.
ing the final weight of the microparticles produced by 
the weight of the BSA added. The yield was calculated 
according to this equation:
% Yield = (WM / WBSA+ Drug)× 100
where, the WM is the final weight of the microparticles 
after drying whilst W BSA+ Drug is the sum of initial weight 
of BSA and drug.
Entrapment efficiency: (Dandagi et al., 2006; Yeo et 
al., 2004; Thakkar et al., 2005; Gupta et al., 2009)
·	 Unentrapped drug: Ten milliliter of pH 7.4 phos-
phate buffer saline (PBS) was added to 10 mg of 
microparticles and this mixture was kept in an ul-
trasonicator for 1 minute. After centrifugation, the 
supernatant was filtered through a 0.45 μm filter and 
the filtrate was suitably diluted with buffer solution. 
The absorbance of resulting solution was measured 
at 237 nm by using UV-visible spectrophotometer. 
The standard calibration curve of diltiazem HCl was 
carried out by using UV-visible spectrophotometer 
and HPTLC. (Figure 2)
·	 Entrapped drug: The residue obtained on centri-
fugation was mixed with 5 mL 0.1 N hydrochloric 
acid containing 2% w/v pepsin and allowed to stand 
for 24 hours. The dispersion was then shaken with 
methylene chloride to extract diltiazem HCl. The 
organic extract was evaporated to dryness and the 
residue dissolved in methanol. The absorbance of 
the resulting solution was measured at 240 nm on 
a UV-visible spectrophotometer to determine the 
amount of Diltiazem HCl present in the micropar-
ticles.
Drug entrapment efficiency = (M actual / M theoretical) x 100% 
Particle size distribution and morphology of 
microparticles (Mathew et al., 2007; Dandagi et al., 
2006; Yeo et al., 2004; Gupta et al., 2009)
Size and morphology (shape and surface characteris-
tics) were characterized by scanning electron microscopy 
using JEOL-T330A scanning microscope (Japan). Dry mi-
croparticles were placed on an electron microscope brass 
stub and coated with gold in an ion sputter. Pictures of 
microparticles were taken by random scanning of the stub. 
The diameter of about 100 microparticles was measured 
from optical microscope of each batch. Finally, average 
mean diameters were obtained (Table I).
FIGURE 2 - Standard calibration curve of diltiazem HCl.
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In vitro drug release studies (Salem et al., 2011; Gupta 
et al., 2009; Oner et al.,1993; Shenoy et al., 1997)
Drug-loaded microparticles equivalent to 50 mg of 
drug were weighed and transferred in to a 100 mL conical 
ﬂask. To this 50 mL of 7.4 pH PBS was added, then the 
ﬂasks were kept in a metabolic shaker and the shaker was 
adjusted to 50 horizontal shakes/min at 37±0.5 ºC. One 
milliliter of the drug releasing media was withdrawn at 
various time intervals of 15 min, 1, 2, 4, 6, 8, 12, 16, 20 
and 24 h and replaced by the same volume of phosphate 
buffer saline (PBS). These samples were filtered though 
0.45 μm membrane filter. The filtrate was diluted suitably. 
The drug was estimated in each batch by UV–Vis spectro-
photometer at 237 nm. For batch DTM-1, the drug release 
study was carried by HPTLC method for comparing the 
results, which are coming from UV-Visible spectroscopy.
In vivo drug distribution studies (Dandagi et al., 2006; 
Gupta et al., 2009; Oner et al.,1993; Shenoy et al., 
1997)
This study was carried out to compare the targeting 
efficiency of drug-loaded microparticles and controlled 
release with that of the free drug in terms of percentage 
increase in targeting to various organs of reticule endothe-
lial system like liver, lungs, kidney and spleen.
Thirty healthy adult Albino mice weighing 35-
40 g were selected, a constant day and night cycle was 
maintained and they were fasted for 12 h. The animals 
were divided into six groups each containing five mice. 
Groups I, II and III received microparticles equivalent to 
700 mg of diltiazem HCl intravenously in the tail vein after 
re-dispersing in sterile phosphate buffer saline solution. 
Microparticles from batch DTM-3 were selected for the 
study. Groups IV and V received 700 mg of pure diltiazem 
HCl drug intravenously and Group VI was kept as solvent 
control and received only saline phosphate buffer.
After 1 h the Groups I, IV and VI mice were 
sacrificed and their liver, lungs, kidney and spleen were 
isolated. The Group V was sacrificed after 2 h and Groups 
II and III were sacrificed after12 and 24 h, respectively. 
The individual organs of each mice were homogenized 
with adding small quantity of phosphate saline buffer pH 
7.4 and 0.1 N HCl, then kept in fridge for 12 h to precipi-
tate protein and then centrifuged at 15,000 rpm to obtain 
the supernatant. The supernatant was filtered though an 
ultrafilter membrane of pore size 0.2 μm and drug content 
was estimated using UV spectrophotometer at 237 nm.
Stability study (Oliva et al., 1999; Kulkarni et al., 2004)
All the eight batches of Diltiazem HCl micropar-
ticles were tested for stability. All the preparations were di-
vided into three sets and were stored at 4 ºC (refrigerator), 
ambient temperature/humidity and 40 ºC (thermostatic 
oven). After 15, 30 and 60 days, drug content of all the 
formulations was determined by the method discussed pre-
viously in entrapment efficiency section. In vitro release 
study was also carried out of the best one formulation.
RESULTS
Microparticles based on the biodegradable polymer 
bovine serum albumin (BSA) have been extensively in-
vestigated as controlled drug delivery system because of 
their excellent biocompatibility and biodegradability. In 
recent years, a continued interest in BSA microparticles 
has been triggered by their application for the controlled 
release of different variety of drugs.
In the present study BSA microparticles encapsu-
lated with Diltiazem HCl were prepared by emulsification-
heat stabilization and emulsification-polymerization tech-
nique. When the primary emulsion is unstable, encapsula-
tion efficiency is low because the internal aqueous phase 
tends to merge with the neighboring aqueous continuous 
phase. Stability of the primary emulsion can be enhanced 
by including emulsifying agents such as PVA, Tween-80, 
or Span-80 either in the internal aqueous phase or in the 
polymer phase.
The percentage practical yield value of micropar-
ticles prepared with Bovine Serum Albumin was in range 
of 65.46% to 72.82% (Table I). The yield value increased 
as the amount of polymer added to each formulation in-
creased. Maximum yield was found to be 72.82% (w/w) 
in DTM-4. 
The encapsulation (drug loading) efficiency for the 
formulated microparticles are summarized in Table I. the 
amount of drug bound per 10 mg microparticles was de-
termined in the prepared all four batches. The maximum 
drug loading was found in DTM-4 (72.48%).
In the present investigation, the particle size dis-
tribution of the microparticles prepared with BSA could 
be changed by simple altering the drug to polymer ratio. 
When related factors such as emulsification stirring speed, 
heating time, solvent to polymer ratio and surfactant/sta-
bilizer concentration were kept constant, an increasing in 
polymer loading elicited a change in microparticles size 
distribution. Scanning electron photomicrographs of all 
the four formulations are shown in Figure 3. An increase in 
the albumin concentration from led to significant increase 
in the particle size. Average particle size of bovine serum 
albumin microparticles of diltiazem HCl was found to be 
2.17, 2.34, 2.48 and 8.25 μm for DTM-1, DTM-2, DTM-3 
and DTM-4 respectively. (Table I). The SEM photomicro-
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FIGURE 3 - Scanning Electron Microscopy (SEM) of diltiazem HCl microparticles, DTM-1 (A), DTM-2 (B), DTM -3 (C) and 
DTM -4 (D).
graphs (Figure 3) of the microparticles reveal that they are 
spherical, nonporous, and uniform with a smooth surface, 
which was prepared by heat stabilization technique. The 
particles appeared to be aggregate in nature without evi-
dence of any collapsed particles.
The cumulative percent drug release of pure drug 
was found to be 97.95% at 2 hours. Cumulative percent of 
drug release after 24 hours was 89.42%, 87.48%, 76.65%, 
and 74.83% for DTM-1, DTM-2, DTM-3 and DTM-4 
respectively by using UV spectroscopy. It was observed 
that the drug release from the formulations decreased with 
increase in the amount of polymer added in each formula-
tion (Figure 4). The in vitro release of all the batches of 
microparticles showed a bi-phasic release with an initial 
burst effect. The drug release from BSA microparticles 
can usually be divided into an initial release (burst) phase 
followed by a slower continuous release phase. The initial 
release, which plays an important role in the therapeutic ef-
ficacy of microparticles, is normally defined as the amount 
of drug released during the first hour. The initial release is 
commonly attributed to the release of drug located close 
to the surface of microparticles. It is related to the micro-
structure (porosity) of the microparticles. In the first hour, 
drug release was 24.82%, 26.67%, 27.28% and 28.92% 
for DTM-1, DTM-2, DTM-3 and DTM-4 formulations 
respectively. Afterwards the drug release followed a steady 
pattern approximating zero order release. An alternative 
method to estimate the drug release concentration of for-
mulation DTM-1 was carried out by HPTLC. The graph 
of HPTLC is shown in Figure 5.
The regression coefficient for formulations DTM-1, 
DTM-2, DTM-3, and DTM-4 of zero-order plot was found 
to be 0.9339, 0.9551, 0.9633 and 0.9973 respectively. The 
regression coefficient for formulations DTM-1 to DTM-
4 of first-order plot was found to be −0.9882, −0.9933, 
−0.9901 and −0.9767 respectively. The regression coef-
ficient for formulations DTM-1 to DTM-4 of Higuchi 
Matrix plot was found to be 0.9871, 0.9929, 0.9959 and 
0.9871 respectively. Hixson Crowell plot regressions coef-
ficient of formulations DTM-1 to DTM-4 was found to be 
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−0.9775, −0.9908, −0.9935 and −0.9808 respectively. The 
slope ‘n’ values in Peppas model for DTM-1 to DTM-4 
were 0.355, 0.324, 0.296 and 0.242 respectively, which is 
less than 0.45.
The average drug distribution efficiency of drug-
loaded microparticles was found to be 15.22% in liver, 
7.86% in lungs, 6.50% in spleen and 4.47% in kidneys 
after 24 hours, whereas accumulation of pure drug in liver 
was 5.89%, in lungs it was 3.48%, in spleen 2.06% and in 
kidneys 1.43% of the injected dose after 2 hours (Table II).
In vitro release studies revealed that the formula-
tion (DTM-3) stored at 4 oC showed 76.84% release, the 
one which was stored at ambient temperature/humidity 
showed 78.27% and 40 oC batch showed 78.68% release 
after 24 hours.
DISCUSSION
In the present study, an attempt is made to formulate 
diltiazem HCl as micro-particulate drug delivery system 
in order to localize drug at the absorption site, enhances 
its bioavailability, reduces dose, thereby improving patient 
compliance. Microparticulate system of diltiazem HCl 
was formulated using BSA (natural polymer) as carrier 
by emulsification–heat stabilizing method. Prior to for-
mulation, preformulation studies were carried out in order 
to establish compatibility between drug and polymer by 
FTIR spectroscopy.
Percentage practical yield was found to be maxi-
mum in formulation DTM-4. Percentage practical yield 
increased as the amount of polymer added to each formu-
lation increased, although it may not be dependent upon 
drug concentration in the formulation. Particle size of 
the drug-loaded microparticles revealed that the particles 
were in micron range. The particle size of the albumin 
microparticles is 2-9 μm. The microparticles describes in 
this study were spherical, smooth surfaced and without 
porous which prepared by heat stabilization technique. 
The microparticles appeared to be aggregate in nature 
without evidence of any collapsed particles. Drug entrap-
ment efficiency was found to be maximum in DTM-4. It 
is observed that drug entrapment efficiency increased with 
increase drug-polymer ratio.
Release of diltiazem HCl from BSA microparticles 
was prolonged with a slight burst release in the first hours 
(Figure 4). The release from microparticles continued for 
TABLE II - In vivo tissue distribution studies of bovine serum albumin microparticles of diltiazem HCL and Pure drug (diltiazem HCl).
Organs
Drug Content (% in w/v)
Microparticles of diltiazem HCl Pure drug
Group I After 1 h Group II After 12 h Group III After 24 h Group IV After 1 h Group V After 2 h
Liver 30.16 27.68 15.22 17.76 5.89
Lungs 16.48 14.52 7.86 13.18 3.48
Kidney 13.42 11.63 6.50 9.83 2.06
Spleen 10.62 9.28 4.67 6.96 1.43
FIGURA 4 – Plots of cumulative % drug released vs. time (in 
vitro release profile) (zero order kinetics).
FIGURE 5 - 3D view of HPTLC of in vitro release profile of 
DTM-1 formulation (First four tracks for standard calibration 
peak, tracks 5-13 are drug release samples and last track for 
maximum drug concentration in the formulation).
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at least 24 hours and fit a zero order release pattern. Within 
24 hours, about 90% of loaded drug in microparticles 
was released. Cumulative percent of drug release with 
respect to time was found to be highest for formulation 
DTM-1 and the lowest for formulation DTM-4. Based 
on the regression coefficient values, the best-fit model for 
DTM-1, DTM-2 and DTM-3 was first order and DTM-4 
followed zero-order release. Results of Hixson Crowell 
plot indicated that DTM-3 and DTM-4 appear to fit this 
model. It was also observed that DTM-3 followed Higuchi 
matrix suggesting drug release by diffusion. The ‘n’ values 
of Peppas suggest Fickian release and Hixson Crowell 
regression data show that formulations also appear to re-
lease drug by erosion mechanism and the release is drug 
dissolution limited.
Figure 7 shows degradation of the microparticles by 
erosion and hydrolysis mechanism. The photograph on 0 
hour (A) shows the appearance of microparticle before 
erosion. The surface of microparticles becomes irregular 
and porous during the erosion (B) after first hour. It was 
noticed in photograph on 24 hours (C) that microparticles 
had broken down to small fragments due to erosion.
Overall, the curve fitting into various mathematical 
models was found to be good and the in vitro release, of 
formulations, best fitted into the Peppas model followed 
by Higuchi’s and Hixson Crowell model (Figure 6). On 
the basis of drug content, particle size morphology, in 
vitro release kinetics, formulation DTM-3 was selected as 
an optimum formulation for in vivo and stability studies.
Figure 5, 3D view of HPTLC of in vitro release pro-
file of DTM-1 formulation. First four tracks for standard 
calibration peak, tracks 5-13 are drug release samples and 
last track for maximum drug concentration in the formula-
tion. The fifth track of the figure indicates burst effect and 
6th to 13th track indicate zero order release pattern.
The present study shows that the targeting efficiency 
of drug-loaded microparticles over free drug was higher, 
which may provide increased therapeutic efficacy. More-
FIGURE 6 – Plots of cumulative % drug released vs. root time 
(in vitro release studies) (Higuchi matrix).
FIGURE 7 – Scanning electron microscopy of before and after in vitro release microparticles of DTM-2: before erosion (A), after 
1 h erosion (B) and after 24 h (C).
over, higher concentration of drug targeted to various or-
gans may help in reduction of dose required for the therapy 
and thereby dose related side effects could be minimized. 
The in vivo drug targeting studies revealed the following 
order of targeting (tissue distribution): liver > lungs > 
kidneys > spleen.
Drug content data of stability studies indicate that 
maximum drug was retained by formulation DTM-3 when 
stored at 4 ºC. Drug content of the formulation DTM-3 
stored at various temperature conditions reduced in the 
following order: 4 ºC > RT > 40ºC. In vitro release data 
of stability studies indicate that very less variation in 
release was found at 4 ºC followed by room temperature 
and 40 ºC.
CONCLUSION
We showed that microparticles of biodegradable 
polymer were promising as a controlled-release drug 
delivery system of diltiazem HCl. Bovine serum albumin 
which are biocompatiable and biodegradable, have stud-
ied for the controlled release of many drugs. From the 
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experimental results obtained with respect to particle size 
and prolonged drug release, it may be concluded that the 
developed bovine serum albumin (biodegradable) mic-
roparticles could be useful for once-a-day intravenous (IV) 
administration of diltiazem HCl. Further, pharmacokinetic 
and drug release model studies are required to confirm the 
application of these microparticles for IV administration. 
From the above studies, it can be concluded that 4 ºC is 
the most suitable temperature for storage of diltiazem HCl 
microparticles.
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